4D Molecular Therapeutics Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease at NACFC 2022

Cohort 1 lung bronchoscopy sample results demonstrate widespread delivery and expression of the 4D-710 CFTR∆R transgene in 100% of samples from all three patients

• Cohort 1 safety and tolerability of 4D-710 demonstrated to date, with no drug-related adverse events following aerosol delivery
• Cohort 1 enrollment completed; Cohort 2 enrollment on-going
• Conference call & webcast to be held today at 1:30 p.m. PT

Excerpt from the Press Release:

EMERYVILLE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that interim clinical data from the Phase 1/2 clinical trial of 4D-710 for cystic fibrosis lung disease were presented at the North American Cystic Fibrosis Conference (NACFC). The presentation focused on safety, tolerability, and delivery and expression of the 4D-710 CFTR∆R transgene in lung tissue samples from patients enrolled in cohort 1 (n=3; 1E15 vg). 4D Molecular Therapeutics will host a conference call today, November 3, 2022, at 1:30 p.m. PT to discuss the interim clinical data.

“We are honored by the selection of our late-breaking clinical data for presentation both in the NACFC symposium today and in the clinical plenary session tomorrow,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. “These landmark CFTR expression data were achieved in the CF population with the highest unmet medical need, those who are not eligible for CFTR modulators. These interim results underscore the encouraging potential of 4D-710 for patients with cystic fibrosis lung disease, and the potential of our proprietary A101 vector for other lung diseases. Finally, these results further validate our Therapeutic Vector Evolution platform.”

Dr. Jennifer L. Taylor-Cousar, Professor, Departments of Medicine and Pediatrics, and Co-Director, Adult Cystic Fibrosis Program; Director, Cystic Fibrosis Foundation Therapeutics Development Center, National Jewish Health; and the lead principal investigator on the 4D-710 phase 1/2 clinical trial, presented the clinical data at the NACFC 2022 conference.

Click the button below to read the entire Press Release:

Continue Reading The Press Release